Tags

Type your tag names separated by a space and hit enter

Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure.
J Glaucoma 1999; 8(2):117-23JG

Abstract

PURPOSE

To prospectively study the effect of oral brovincamine, a relatively selective cerebral vasodilator, on further deterioration of visual field in patients with normal-tension glaucoma (NTG) with low-normal intraocular pressure (IOP).

METHODS

Fifty-two patients with NTG (average age 57.7 years) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine (20 mg three times daily) or to an untreated control group. The groups were prospectively followed for 2 years with visual field examinations every 4 months, using the 30-2 Humphrey perimeter program. Changes in mean deviation (MD), corrected pattern standard deviation (CPSD), and total deviation (TD) at 74 test points were analyzed using regression analysis with linear mixed model. Data from one eye without media opacity of each subject were analyzed.

RESULTS

There were no differences between groups in age; sex distribution; refraction; blood pressure; baseline IOP; MD, CPSD, or TD at each point. Changes in MD (standard error [SE]) during the study period were -0.778 (0.178) and -0.071 (0.195) dB/year in the control and brovincamine groups, respectively; change in the control group was significantly more negative than in the brovincamine group. Change in CPSD (SE) was 0.032 (0.015) and 0.004 (0.016) dB/year in the control and brovincamine groups, respectively. Change in the control group was significantly positive, but the intergroup difference was not significant. Change in TD was significantly negative at six test points in the control group, whereas no points showed a significant trend in the brovincamine group; the intergroup difference was significant. The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups, respectively, and there was no significant intergroup difference.

CONCLUSION

Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP.

Authors+Show Affiliations

Department of Ophthalmology, University of Tokyo School of Medicine, Japan.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10209728

Citation

Koseki, N, et al. "Effects of Oral Brovincamine On Visual Field Damage in Patients With Normal-tension Glaucoma With Low-normal Intraocular Pressure." Journal of Glaucoma, vol. 8, no. 2, 1999, pp. 117-23.
Koseki N, Araie M, Yamagami J, et al. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. J Glaucoma. 1999;8(2):117-23.
Koseki, N., Araie, M., Yamagami, J., Shirato, S., & Yamamoto, S. (1999). Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. Journal of Glaucoma, 8(2), pp. 117-23.
Koseki N, et al. Effects of Oral Brovincamine On Visual Field Damage in Patients With Normal-tension Glaucoma With Low-normal Intraocular Pressure. J Glaucoma. 1999;8(2):117-23. PubMed PMID: 10209728.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. AU - Koseki,N, AU - Araie,M, AU - Yamagami,J, AU - Shirato,S, AU - Yamamoto,S, PY - 1999/4/21/pubmed PY - 1999/4/21/medline PY - 1999/4/21/entrez SP - 117 EP - 23 JF - Journal of glaucoma JO - J. Glaucoma VL - 8 IS - 2 N2 - PURPOSE: To prospectively study the effect of oral brovincamine, a relatively selective cerebral vasodilator, on further deterioration of visual field in patients with normal-tension glaucoma (NTG) with low-normal intraocular pressure (IOP). METHODS: Fifty-two patients with NTG (average age 57.7 years) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine (20 mg three times daily) or to an untreated control group. The groups were prospectively followed for 2 years with visual field examinations every 4 months, using the 30-2 Humphrey perimeter program. Changes in mean deviation (MD), corrected pattern standard deviation (CPSD), and total deviation (TD) at 74 test points were analyzed using regression analysis with linear mixed model. Data from one eye without media opacity of each subject were analyzed. RESULTS: There were no differences between groups in age; sex distribution; refraction; blood pressure; baseline IOP; MD, CPSD, or TD at each point. Changes in MD (standard error [SE]) during the study period were -0.778 (0.178) and -0.071 (0.195) dB/year in the control and brovincamine groups, respectively; change in the control group was significantly more negative than in the brovincamine group. Change in CPSD (SE) was 0.032 (0.015) and 0.004 (0.016) dB/year in the control and brovincamine groups, respectively. Change in the control group was significantly positive, but the intergroup difference was not significant. Change in TD was significantly negative at six test points in the control group, whereas no points showed a significant trend in the brovincamine group; the intergroup difference was significant. The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups, respectively, and there was no significant intergroup difference. CONCLUSION: Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP. SN - 1057-0829 UR - https://www.unboundmedicine.com/medline/citation/10209728/Effects_of_oral_brovincamine_on_visual_field_damage_in_patients_with_normal_tension_glaucoma_with_low_normal_intraocular_pressure_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=10209728.ui DB - PRIME DP - Unbound Medicine ER -